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Abstract
Prognostic factors in organ confined prostate cancer will reflect survival after surgical radical
prostatectomy. Gleason score, tumour volume, surgical margins and Ki-67 index have the most
significant prognosticators. Also the origins from the transitional zone, p53 status in cancer tissue,
stage, and aneuploidy have shown prognostic significance. Progression-associated features
include Gleason score, stage, and capsular invasion, but PSA is also highly significant. Progression
can also be predicted with biological markers (E-cadherin, microvessel density, and aneuploidy)
with high level of significance. Other prognostic features of clinical or PSA-associated progression
include age, IGF-1, p27, and Ki-67. In patients who were treated with radiotherapy the survival was
potentially predictable with age, race and p53, but available research on other markers is limited.
The most significant published survival-associated prognosticators of prostate cancer with
extension outside prostate are microvessel density and total blood PSA. However, survival can
potentially be predicted by other markers like androgen receptor, and Ki-67-positive cell fraction.
In advanced prostate cancer nuclear morphometry and Gleason score are the most highly
significant progression-associated prognosticators. In conclusion, Gleason score, capsular invasion,
blood PSA, stage, and aneuploidy are the best markers of progression in organ confined disease.
Other biological markers are less important. In advanced disease Gleason score and nuclear
morphometry can be used as predictors of progression. Compound prognostic factors based on
combinations of single prognosticators, or on gene expression profiles (tested by DNA arrays) are
promising, but clinically relevant data is still lacking.
Introduction
Prostate cancer is the most common malignancy in men
and the second leading cause of cancer death in the West-
ern world [1-3]. Today, more patients with prostate cancer
are being diagnosed in early stages of the disease than
used to be the case 10 years ago. The increasing incidence
may be due to increased PSA-measurements and other
diagnostic efforts. However, this review does not handle
the associated differential diagnosis. Also, the biological
heterogeneity that characterizes this disease causes deci-
sion issues unique to prostate cancer. Low-grade cancer
diagnosed late in life may have no impact on the quality
or length of life. A younger man with a high-grade lesion
may have advanced disease and die within a couple of
years. Biological distinction of such patients should have
a high priority in continuing research.
Although prostate cancer is very prevalent among men,
relatively little is known about the molecular mechanisms
involved in the development and progression of the dis-
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ease [4-7]. The lack of knowledge on the biology of pros-
tate cancer has resulted in numerous controversies on the
clinical management of the early stages and on the utility
of population screening [8].
One of the aims of molecular genetics is to reveal the
genetic alterations and genes that are involved in disease
processes. Molecular pathogenesis of the prostate cancer is
poorly understood. Over the past 10 years, chromosomal
aberrations in prostate cancer have been studied with sev-
eral techniques, such as loss of heterozygosity (LOH), flu-
oresence in situ hybridization (FISH), comparative
genomic hybridization (CGH), suppression substractive
hybridization (SSH) and cDNA array hybridization. FISH
has been used to identify the target genes for some of these
chromosomal alterations [9]. These chromosomal altera-
tions are most likely to harbour the genes critical for the
progression of prostate cancer [10].
After the diagnosis is established, the physician wants to
determine whether the lesion is confined to the prostate
gland (and is hence potentially curable), or whether can-
cer has spread beyond the prostate and is incurable. At the
present time, the successful radical treatment of prostate
cancer is limited to the patients with organ-confined dis-
ease.
On the other hand, there are also latent prostate cancers.
Most patients with latent prostate cancer die with, rather
than of, prostate cancer. Against this background we
should concentrate in finding objective criteria for distin-
guishing between clinically significant and clinically
insignificant cancers, usually falling into the category of
latent prostate cancer [11]. In other words, it is becoming
increasingly important to find factors, which could pre-
dict which patients have tumours with aggressive invasive
potential to spread outside the prostate [12]. Various
types of clinical and pathological information may con-
tribute in building decision making systems or tools for
this purpose. Clinicians treating prostate cancer patients
may potentially use these tools.
The management could be in the form of early detection
and identification of prognostic factors, which help in
forecasting the outcome in an individual case. Perfect
forecasting could help in selecting the treatment mode
that would be most appropriate for the treatment of an
individual patient. So patients with favourable outcome –
if identified – would not need crippling therapy whereas
patients with a high risk of early metastasis or death
would be placed in the group of more intensive treatment
and surveillance follow up. This is also important after
surgical radical prostatectomy, which offers lot of material
for analysis and creates a challenge for the pathologists
[13]
Unfortunately, general reliable forecasting of the outcome
is still not possible, and efforts to identify prostate cancer
prognosticators must continue [14]. So, it is important to
answer the question: What are the histolgical, cell biolog-
ical and molecular features which could differentiate
between aggressive and non-aggressive types of prostate
cancer?
The intention of this review is to shed light on the above
questions by reviewing the most widely studied prognos-
tic factors to help the clinicians to create practical prog-
nostic models that can potentially also help in
individualization of the treatment. Some of these impor-
tant prognostic factors are summarized in Table 1.
Clinico-pathological prognostic factors
Clinical prognostic factors are those that can be assessed
through physical examination: blood tests, radiological
evaluation, and microscopy of biopsy material. Clinical
factors are important because they allow the cancer to be
characterized before a definitive treatment decision is
made. In this review article, pathological prognostic fac-
tors are those that require examination, removal, and
evaluation of the entire prostate.
Age of patient
The role of the age of the patient per se as a significant
prognostic factor in prostate cancer is controversial
[15,16]. 567 patients completing external beam radio-
therapy were examined by Herold et al [17]. In addition
to other factors, age of the patients greater than 65 years
was a significant predictor of distant metastases at 5 years.
They concluded that men over the age of 65 years were
more likely to experience distant failure after radical radi-
ation therapy than were younger men. Obek et al [18] also
suggested that young age per se might be an independent
favourable prognostic factor for disease recurrence after
surgical radical prostatectomy. Also Freedland et al [19]
found that young men had more favourable outcomes
after surgical radical prostatectomy (RP) than older men,
which made younger men suitable subjects in screening.
Volume
Although tumour volume is an important factor in pre-
dicting prognosis in carcinoma of the prostate, direct and
accurate estimation of tumour volume is not practical
clinically. This is because the tumour may not always be
palpable, and when palpable the volume cannot be eval-
uated in 3 dimensions [20]. Transrectal ultrasound
(TRUS) used as a tool for estimating the tumour volume
either directly (Terris et al 1992) [21] or as a guide for core
biopsies [22,23] has only limited ability to estimate pros-
tate cancer volume. 176 radical prostatectomy specimens
were studied with respect to cancer volume by McNeal et
al [24]. They found that the extent of capsular penetration,Diagnostic Pathology 2006, 1:4 http://www.diagnosticpathology.org/content/1/1/4
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cancer volume, and positive nodes were strongly inter-
correlated. Twelve cubic centimetres was the critical vol-
ume. Higher volumes were usually associated with exten-
sive capsular penetration, positive surgical margins, and/
or positive nodes.
To determine which of these three variables provided
independent prediction of prognosis Epstein et al [25]
evaluated 185 men following surgical radical prostatec-
tomy for stage T2 disease. The patients were re-evaluated
at 5 years after prostatectomy and grouped into 2 groups:
those free of disease, and those who experienced progres-
sion. The study accepted only cases with negative pelvic
lymph nodes and with negative seminal vesicles at the
time of the diagnosis. At five years following radical pros-
tatectomy, 58 men (31%) had experienced progression.
Gleason grade, surgical margins, and tumour volume each
where highly correlated with progression. In stepwise
regression analysis, tumour volume did not provide inde-
pendent prognostic information beyond that provided by
Gleason score and the status of surgical margins.
The study by Bostwick et al [26] for evaluating the utility
of tumour volume in predicting progression of early pros-
tate cancer revealed that tumour volume was a significant
predictor of cancer progression. They found that there was
a 10% probability of capsular invasion in tumours meas-
uring about 0.5 cm3, 10 % probability of seminal vesicle
invasion in tumours measuring about 4.0 cm3, and 10 %
probability of distant metastases in tumours measuring
Table 1: Prognostic factors associated with prostate cancer after different types of treatment and according to the level of extension. 
Patients with organ confined disease treated with radical prostatectomy (surgical or radiated), and patients with more extensive 
disease are presented separately. The database applied was PubMed, the presented papers were published during years 1989 – 2005.
Organ confined disease, radical prostatectomy (surgical)
Survival-associated prognosticators Progression-associated prognosticators
Prognosticator p value Reference Prognosticator p value Reference
Tumour volume < 0.009 Salomon et al. Age < 0.01 Obek et al.
Gleason score < 0.0002 Hoznek et al. Gleason score < 0.0001 Epstein et al.
Surgical margin < 0.009 Hoznek et al. Capsular invasion < 0.001 Wheeler et al.
Tranzitional zone < 0.04 Augustin et al. PSA* < 0.001 Salomon et al
p53 < 0.011 Kuczyk et al. Surgical margin < 0.075 Bloom et al.
Stage < 0.02 Kuczyk et al. E-cadherin < 0.005 Umbas et al.
p27 < 0.01 Yang et al. IGF-1** < 0.05 Yu et al.
Aneuploidy < 0.02 Zincke et al. Stage < 0.001 D'Amico et al.
Ki-67 < 0.001 Bettencourt et al. MVD*** < 0.007 Halvorsin et al.
cDNA microarray < 0.01 Susan et al. p27 < 0.008 Yang et al.
Aneuploidy < 0.0001 Zincke et al.
Aneuploidy < 0.001 Ross et al.
Ki-67 < 0.02 Bubendorf et al.
MUC1 < 0.003 Lapointe et al.
Organ confined disease, radical prostatectomy (radiation)
Survival-associated prognosticators Progression-associated prognosticators
Prognosticator p value Reference Prognosticator p value Reference
Age < 0.02 Austin el al.
Age < 0.01 Neulander et al
Race < 0.02 Austin et al.
Gleason score < 0.001 Kupelian et al.
p53 < 0.02 Grignon et al.
Radiation dose < 0.001 Kupelian et al.
Prostate cancer with extension outside the prostate (advanced disease)
Survival-associated prognosticators Progression-associated prognosticators
Prognosticator p value Reference Prognosticator p value Reference
AR**** < 0.01 Segawa et al. Nuclear morphometry < 0.01 Partin et al.
AR < 0.02 Miyoshi et al. Nuclear morphometry < 0.0003 Vesalainen et al.
Total-PSA < 0.001 Bjork et al. Gleason score < 0.0001 Vesalainen et al.
MVD < 0.0001 Borre et al. Gleason score < 0.007 Shurbaji et al.
Ki-67 < 0.02 Aaltomaa et al. AR < 0.03 Sadi et al.
p53 < 0.018 Bauer et al.
bcl-2 < 0.004 Bauer et al.
* Prostate Specific Antigen, ** Insulin-like Growth Factor, *** Microvessel density, **** Androgen ReceptorDiagnostic Pathology 2006, 1:4 http://www.diagnosticpathology.org/content/1/1/4
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about 5.0 cm3. As described by McNeal et al [27] loss of
differentiation and potential to give rise to metastases
were strongly correlated with tumour volume. In contrast
to the previous results, Salomon et al [28] showed that
tumour volume does not provide additional information
to predict prostate cancer progression after radical prosta-
tectomy. The same was concluded by Kikuchi et al [29].
Simply because tumour volume does not give additional
prognostic value to the Gleason score, many centers do
not consider it valuable in clinical practice [13]. However,
if better prognosticators are not available, the volume is
still a valuable guide in prognostication.
Grading
All existing grading systems successfully identify well-dif-
ferentiated cancer, which progresses slowly, and poorly
differentiated cancer, which progresses rapidly, but they
are less successful in subdividing moderately differenti-
ated cancers, which have an intermediate malignant
potential [30]. The histological Gleason score of the ade-
nocarcinoma of the prostate is a good and an established
prognostic indicator.
Dr Donald F Gleason [31] and members of the Veterans
Administration Cooperative Urological Research Group
devised the Gleason grading method in the 1960s and
1970s. This grading system is based entirely on the histo-
logical pattern of differentiation and arrangement of car-
cinoma cells and cell groups in H&E-stained sections. Five
basic patterns (scored 1–5) are used to generate a histo-
logical sum score (summed from scores of two most dom-
inant patterns), which can range from 2 to 10 [32].
Gleason grading of the cancer is the most widely used, and
accepted histopathological method for providing infor-
mation about the prognosis of prostate cancer. Univariate
and multivariate analyses of prognosis in prostate cancer
almost always identify Gleason grade as one of the most
significant predictors of patient outcome [33]. A 3-grade
grading system is also in use, but no longer recommended
[13]. Also, models have been developed which allow for
pre-treatment prediction of pathologic stage on the basis
of needle biopsy Gleason grade, total serum prostate-spe-
cific antigen level, and clinical stage [34]. It is of consider-
able interest to know how accurate the needle biopsy
Gleason score is in relation to Gleason score obtained
from the radical prostatectomy samples [35]. Over half of
the patients are under- or over-graded by needle biopsy.
Clinicians should be aware of this potential inaccuracy
when using Gleason grading in decision-making [36].
Koksal et al [37] found that grading error was greatest in
well-differentiated tumours and true sum scores between
2–4. The grading error decreased with increasing Gleason
score. The same was concluded by Shen et al [38].
Tumours with combined Gleason scores of 2–4 are not
commonly present in needle biopsy material, since palpa-
ble tumours are usually of a higher grade [39].
Two important studies [40,41] have demonstrated a good
correlation between the prognosis of prostate cancer and
combined Gleason scores. Even when a high-grade
tumour is organ confined, it is associated with a relatively
unfavourable short-term outcome that is not predictable
on the basis of either preoperative clinicopathologic data
or postoperative pathologic information obtained from
the radical prostatectomy specimen [42]. The study by
Cheng et al [43] showed that the combined percentage of
Gleason patterns 4 and 5 is the best predictor of progres-
sion after radical prostatectomy. This is why the percent-
age of patterns 4 and 5 should today be reported in
histopathological evaluation. With Partin coefficient
tables it is possible to calculate risks for recurrence [44]
Extracapsular extension
In rectal examination the incidence of capsular penetra-
tion in palpable clinically confined tumours is 20–38% or
40–66% (unilateral or bilateral tumours, respectively)
[45,46]. The study of 196 tumours by Epstein et al [47]
demonstrated that tumours with more extensive capsular
penetration had a higher risk of progression than those
showing focal capsular penetrations. One-hundred thirty
(130) patients with follow up of more than 10 years after
radical prostatectomy were histologically restaged by The-
iss et al [48]. They found that in contrast to capsular inva-
sion as such, capsular penetration is an indicator of poor
prognosis. Capsular penetration was associated with
higher progression rate and reduced survival. They recom-
mended that tumours with capsular invasion and those
with capsular penetration should be distinguished. Ohori
et al [49] found that the probability of progression-free
survival at 7 years was 65% for patients with extracapsular
extension and positive margins and a Gleason score of 6
or less, and 40% for patients with extracapsular extension
and positive surgical margins and a Gleason score of 7 or
more. To assess the relationship between the level and
extent of prostatic capsular invasion by cancer, the clinical
and pathological features, and prognosis of early state
prostate cancer Wheeler et al [50] used multivariate anal-
ysis. They found that the level of capsular invasion was an
independent prognostic factor and a strong association
between the level of invasion of cancer into or through the
prostatic capsule and the volume, grade, pathological
stage, and the rate of recurrence after radical prostatec-
tomy. Also they concluded that sub-classification of
patients according to the levels of prostatic capsular inva-
sion provides valuable prognostic information.
Seminal vesicle invasion
In most recent studies, seminal vesicle invasion (SVI) is a
poor prognostic parameter [51,52], with biochemical pro-Diagnostic Pathology 2006, 1:4 http://www.diagnosticpathology.org/content/1/1/4
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gression-free rates ranging from 5–60%. The differences
may be related to the definition of the seminal vesicle
invasion. Some authors consider an intraprostatic portion
of the seminal vesicle as true seminal vesicle, and as such
consider its involvement by cancer as seminal vesicle inva-
sion. Others call any seminal vesicle as extracapsular
extension [53]. Some studies do not make any distinction
between the seminal vesicles and the ejaculatory duct
complex.
Seminal vesicle invasion is associated with high PSA fail-
ure rates (PSA levels not changed to normal) after radical
prostatectomy, and subsequent distant metastases [54].
Debras et al, [55] evaluated the prognostic significance of
SVI in radical prostatectomy specimens according to prox-
imal or distal site of invasion. They concluded that the
prognostic significance of SVI is not constant and depends
on the site of invasion, in which patients with invasion
extending to the free part of the seminal vesicles have
poorer prognosis than those patients with invasion only
limited to the proximal part of the seminal vesicles.
115 cases of established capsular penetration, 16 of peri-
seminal vesicle invasion, and 45 of seminal vesicle inva-
sion in-patients without lymph node metastases were
evaluated by Epstein et al (1993c). They concluded that
patients with SVI had a significantly worse prognosis than
those with capsular penetration, and peri-seminal vesicle
invasion was associated with an intermediate risk of pro-
gression. The results of Freedland et al [56] revealed that
patients with SVI had significantly higher PSA values,
higher clinical stage, higher grade tumours, and were
more likely to have concomitant extracapsular extension
or a positive surgical margin. The study also identified a
subset of men with low-grade disease, negative surgical
margins, and older age, who – despite SVI – had an
extremely favourable clinical course. The study concluded
that SVI does not consistently suggest an unfavourable
prognosis.
Zone of origin
The development of zonal anatomy of the prostate
reported by McNeal [57,58] allows the assignment of the
zone of origin to individual prostate cancer foci. Cancer
foci detected incidentally in tissue removed by transure-
thral resection of prostate (TURP) (stage A) are predomi-
nantly of transitional zone (TZ), while clinically palpable
(stage B) cancers are predominantly of peripheral zone
(PZ) origin [59]. McNeal identified 68% of small prostate
cancers as originating from the peripheral zone (PZ), 24%
from the transitional zone (TZ), and 8% from the central
zone (CZ).
To determine the characteristics of transition zone and
peripheral zone prostate cancer, Greene et al [60] exam-
ined a series of 42 stage A and 54-stage B radical prostate-
ctomy specimens. They paid particular attention to the
number of separate foci of cancer, zone of origin, volume
and grade of foci, presence of severe intraductal dysplasia,
extra-capsular extension, and seminal vesicle invasion
associated with cancer in each zone. They found that there
were fundamental differences between transitional zone
(TZ) and peripheral zone (PZ) cancers. Cancer that arises
in the transitional zone is associated with more favoura-
ble pathological features and may have less malignant
potential than tumours that arise in the peripheral zone.
The results of Augustin et al [61] showed that patients
with tumours including 70% or more of the cancer vol-
ume in the TZ had a significantly higher rate of biochem-
ical cure than those with 30% or less. Jack et al [62]
revealed that transitional zone tumours were favourable
with higher rate of organ confined and lower grade
tumours. They concluded that if transitional zone
tumours prove to be biologically distinct, improved strat-
egies to identify these lesions preoperatively might result
in more conservative treatment recommendations.
Heterogeneity and multicentricity
As early as 1935, Moore had recognized that prostatic car-
cinomas are often multifocal [63]. Prostatic carcinoma is
characteristically multifocal with as many as 5 or 6
tumours occurring in a single prostate [64]. A great chal-
lenge for diagnostic pathologists was the characteristic
heterogeneous appearance of prostatic carcinoma. The
availability of radical prostatectomy specimens has pro-
vided the opportunity to examine the interrelationships
of histological heterogeneity and multicentricity in indi-
vidual specimens [65]. The influence of grade heterogene-
ity and tumour multifocality on the ability to predict the
prognosis of patients with prostate cancer is profound.
The multifocal and heterogeneous nature of prostate
makes it difficult to obtain representative biopsy samples
from the tumours [66]. Hammerer and associates [67]
considered the number of biopsies positive for cancer as
quantitative measure of tumour multicentricity. The data
of Djavan et al [68] suggested that multifocal prostate can-
cer is associated with higher grade, stage, and recurrence
rate than unifocal prostate cancer.
Morphometric features
In 1982 Diamond and associates introduced nuclear mor-
phometry to aid in prediction of prognosis among
patients with prostate cancer [69,70]. He and his col-
leagues observed that nuclear roundness was very useful
in separating long survivors among stage B patients from
those who develop metastasis. They observed no overlap
in nuclear roundness between the two groups. Since then,
many histological studies [71-75] have used nuclear mor-
phometry to predict prognosis in patients with prostate
cancer. Eichenberger and associates [73] calculated 12Diagnostic Pathology 2006, 1:4 http://www.diagnosticpathology.org/content/1/1/4
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shape descriptors including nuclear roundness, ellipticity
factors, and concavity factors. They used discriminate
analysis to select the major morphometric parameters
which best distinguished patients with good or poor prog-
nosis. Elliptical shape measurement was found to be the
best in this respect.
To evaluate critically the usefulness of nuclear morphom-
etry for prediction of prognosis, Partin et al [75] devel-
oped a morphometric evaluation system called Hopkin's
Morphometry System, and produced and compared 15
different shape descriptors in stage A2 prostate cancer.
These were analysed by 17 different statistical tests. The
best separation was provided by the lower quartile analy-
sis of the ellipticity shape descriptor (p < 0.01). These
studied revealed that elliptical shape of the nuclei is very
important as prognostic factor.
Variance of nuclear roundness combined with clinical
stage, Gleason score, and age produced a prognostic score
capable of stratifying patients with clinically localized
cancers into three groups with different disease free sur-
vival [76].
Aragona et al [77] concentrated on the role of size fea-
tures. They found that accurate prediction for well-differ-
entiated adenocarcinoma was attained using mean
nuclear area (> 28 µm2, mean nuclear diameter (> 5 µm)
and the presence of more than 5% of cells with a nuclear
diameter greater than (6.16 µm).
A series of 325 patients with prostatic adenocarcinoma
were followed-up for over 13 years by Vesalainen et al
[78]. The patients were subjected to histomorphometric
analysis for the following prognostic factors: the Gleason
score and 10 nuclear morphometric factors (mean nuclear
area, nuclear perimeter, and shortest and longest nuclear
factors, form factors and their SDs). They found that in T1-
2M0 tumours, all of these parameters were significant
prognostic factors. The results of study by Martinez-Jaba-
loyas et al [79] revealed that mean nuclear area and other
factors proved to have prognostic value in the univariate
analysis and concluded [80] that nuclear morphometry in
the primitive tumour provides independent prognostic
information in survival analysis for patients with meta-
static prostate cancer. The combined evaluation of high
nuclear morphology, ploidy and cell survival parameters
such as Bcl-2 expression might better identify patients
with poor prognosis among early stage prostate carcino-
mas diagnosed by FNA biopsies [81].
Beside to the prognostic and predictive power of mor-
phometry, Buhmeida et al [82] revealed that the nuclear
size features are useful in distinguishing between different
atypia groups of prostate gland in fine needle aspiration
biopsies, particularly if the sample-associated means of
the size features (area, diameter, perimeter, short and long
axes) are used for the interpretation of data. The study sug-
gested that if the upper range limit of sample-associated
mean areas of nuclei is below 27 µm2, it is most probable
that we are dealing with benign cells. If the upper range
limit is above 39 µm2, it is possible that there are malig-
nant cells in the sample. However, values above 52 µm2
represent malignant samples with certainty. Further stud-
ies will be necessary for associating nuclear size features
with Gleason grades.
Biological prognostic factors
E-cadherin
Normally functioning cell-cell adhesion plays an impor-
tant role in the maintenance of tissue architecture and
cohesion. E-cadherin is an important adhesion molecule
in epithelial cells. E-cadherin expression has been pro-
posed for predicting prognosis in prostate adenocarci-
noma. A study of E-cadherin levels by
immunohistochemistry in nonmalignant and malignant
specimens of human prostatic tissue revealed that almost
50% of tumours examined had reduced levels of this pro-
tein, and in some tumours E-cadherin was absent alto-
gether when compared to non-malignant prostate, which
uniformly stained strongly positive [83]. To determine the
potential prognostic significance of the findings, prostate
cancer specimens from 89 patients were evaluated immu-
nohistochemically using specific antibodies raised against
E-cadherin [84]. The results were related to histological
grade, tumour stage, presence of metastasis, and survival.
Patients showing low immunohistochemical expression
of E-cadherin have on average shorter survival than
patients with high immunohistochemical expression.
Because mutational inactivation of alpha-catenin can be
the cause of the impaired E-cadherin function, Umbas et
al [85] studied the relationship between E-cadherin and
alpha-catenin expression. The results suggest that loss of
alpha-catenin expression could be one of the mechanisms
responsible for the loss of E-cadherin mediated cell-cell
adhesion in human prostate cancer and might in some
cases provide prognostic information. The same was con-
cluded by Aaltomaa et al [86] who studied the expression
of alpha-catenin in locally advanced prostate cancer. They
found that alpha-catenin had prognostic significance in
the early phases of cancer progression. Low alpha-catenin
expression was related to worse prognosis than high
alpha-catenin expression. De-Marzo et al [87] correlated
the down-regulation of E-cadherin and pathologic stage at
radical prostatectomy. In univariate analysis they found
that reduced levels of E-cadherin correlated with advanced
Gleason score (p = 0.003) and advanced pathologic stage
(p = 0.008). In multivariate analysis, E-cadherin, preoper-
ative PSA, and Gleason score all contributed independ-Diagnostic Pathology 2006, 1:4 http://www.diagnosticpathology.org/content/1/1/4
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ently to the prediction of high stage disease (p < 0.001).
They concluded that a prospective study on E-cadherin is
warranted. The study should evaluate E-cadherin as a
potential biomarker of disease progression in patients
with clinically organ-confined prostate cancer who
undergo radical prostatectomy. Moderate or strong
expression of a transcriptional repressor EZH2 (enhancer
of zestor homolog2) coupled with at most moderate
expression of E-cadherin was the biomarker combination
that was most strongly associated with recurrence of pros-
tate cancer [88]. In the clinical situation low E-cadherin
immunostaining suggested clinical recurrence. But to
what extent and at what level of accuracy the status of an
individual patient can be predicted should be evaluated in
further studies.
Insulin-like growth factor (IGF)
The insulin-like growth factor (IGF) system is composed
of two ligands (IGF-I and IGF-II), two receptors (IGFR-I
and IGFR-II) and six binding proteins (IGFBP 1 to 6). Mita
et al [89] found that IGF-II and IGFBP2 play a role in pros-
tate cancer progression and their increased expression is a
prognostic indicator in hormone- treated prostate cancer
patients. The results of the study by Figueroa and co-work-
ers [90] indicate that the higher expression of IGFBPs in
human prostate cancer correlates with the Gleason score,
and the expression of certain IGFBPs may be used as
markers of aggressive clinical behaviour. After studying
changes in IGFBP2 and IGFBP3 levels in serial postopera-
tive serum samples from prostate cancer in patients with
and without relapse, Yu et al [91] suggested that IGFBP2
may play a role in the progression of prostate cancer, but
that serum levels of IGF-I and IGFBP3 have no predictive
value in the progression of prostate cancer. However, the
high preoperative circulating plasma insulin-like growth
factor (IGF-I) levels have been correlated with increased
risk of prostate cancer [92-94].
Androgen receptors (AR)
The androgen receptor (AR) is a nuclear transcription fac-
tor that binds male sex steroids and mediates the biologi-
cal effects of these hormones in the target cells by
activating transcription of androgen-dependent genes.
The AR gene is localized on chromosome X and it con-
tains a series of CAG trinucleotide repeats. The length of
CAG repeats varies among individuals and this polymor-
phism is believed to be related to the transcriptional activ-
ity of AR. Fewer CAG repeats are associated with increased
risk of developing tumour as well as more aggressive
forms of prostate cancer and breast cancer of women [95].
Withdrawal of androgens or peripheral blockade of
androgen action is a critical therapeutic option in the
treatment of advanced prostate cancer. However, after ini-
tial regression, many prostate cancers become hormone
refractory and progress further with eventually fatal out-
come. A large number of different molecular mechanisms
may be responsible for the development of hormone-
refractory recurrent tumours. Many of these involve the
AR gene and its complex downstream signalling pathways
[96]. Mutations in the coding region of the AR gene have
been found in both untreated and hormone-refractory
prostate cancer [97]. Segawa et al [98] demonstrated that
AR expression was significantly lower in adenocarcinoma
than is non-tumour prostate tissues. They also found that
there is significant correlation between progression free
survival and AR expression or proliferative activity. High
AR expression predicted high proliferative activity and
short progression free survival. Similarly, the results of
Miyoshi et al [99] showed the AR expression level in hor-
mone-refractory prostate cancer specimens was signifi-
cantly lower than that in previously untreated prostate
cancer or benign prostatic hyperplasia (BPH) specimens.
The results suggested that a higher AR expression level
result in poor recurrence-free survival and poor overall
survival in hormone-refractory prostate cancer patients.
The greater AR heterogeneity in poor responders may
reflect a greater genetic instability in tumours that have
progressed toward androgen independence i.e., many of
the growth factors may exhibit their effects via crosstalk
with AR [100]. AR heterogeneity may consequently be
used as a predictor of treatment response and as a sign of
progression [101]. Magi-Galluzzi et al [102] suggested
that the heterogeneity in the expression of the androgen
receptors increases with progression of invasive prostate
cancer and might in part account for variable response to
endocrine therapy.
Prostate specific antigen (PSA)
Prostate cancer causes the release of a number of sub-
stances into the blood stream. Of these, prostate specific
acid phosphatase (PSAP) and prostate specific antigen
(PSA) are clinically most important, and can be used for
screening for prostate cancer, and for monitoring the
response to treatment. To a degree PSA also provides diag-
nostic information [103]. Of the molecular forms of PSA,
especially the free PSA seems to be useful for the detection
of prostate cancer in men whose total PSA concentrations
fall in the 4–10 microg/l range [104]. The values of total
PSA (tPSA), free PSA (fPSA) and PSA complexed to
alpha1-antitchymotrypsin (PSA-ACT) are all independent
prognostic factors of prostate cancer survival [105]. Serum
PSA levels are strong prognostic determinants of outcome
following radiotherapy for prostate cancer and appear to
add prognostic information independent of tumour stage
and grade [106]. After radical prostatectomy a rising PSA
level almost always precedes clinical recurrence of carci-
noma [107]Diagnostic Pathology 2006, 1:4 http://www.diagnosticpathology.org/content/1/1/4
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The clinical significance of pre-treatment serum PSA val-
ues studied by Kuriyama et al [108] revealed that serum
PSA can be used to predict the stage and prognosis of pros-
tate cancer. Specifically, preoperative serum PSA levels are
highly predictive of risk of recurrence after radical prosta-
tectomy [109].
Determination of the serum urine PSA ratio enhances the
specificity of PSA in screening, and in monitoring of
patients with prostate cancer under androgen deprivation
therapy [110]. An interesting study by D'Amico et al [111]
revealed that men whose PSA level increases by more than
2.0 ng per millilitre during the year before the diagnosis of
prostate cancer may have a relatively high risk of death of
prostate cancer despite having undergone radical prostate-
ctomy. Pre-treatment PSA level of 20 ng/ml or above, is of
predictive value for the survival of men with clinically
localized prostate cancer. Whether models based on pre-
treatment PSA are as useful for predicting long-term sur-
vival as the other prognosticators like Gleason score, path-
ological lymph node status, and tumour stage will require
further studies of longer follow-up to determine [112].
Microvessel density (MVD)
Tumour growth beyond a certain size requires angiogen-
esis. Once the tumour leaves the pre-angiogenic pheno-
type to become angiogenic, also metastases often start to
evolve. Evaluation of the formation of new blood vessels
has been proposed to provide important prognostic infor-
mation in prostate cancer. The microvessel density count
in the tumour area significantly increased with increasing
Gleason score and nuclear grade. However, corresponding
significant increase was not observed in the adjacent
benign prostate or area of prostatic intraepithelial neopla-
sia (PIN) in the same samples [113]. Hall et al [114] con-
cluded that quantification of tumour angiogenesis might
prove valuable as a negative prognostic indicator in
patients with localized prostate cancer. Borre et al [115]
demonstrated that MVD was a significant predictor of
shorter disease-specific survival in the entire cancer popu-
lation as well as in the clinically localized cancer popula-
tion. Halvorsen et al [116] concluded that in moderately
differentiated prostatic adenocarcinoma MVD might
improve the prognostic stratification of patients after rad-
ical prostatectomy. In contrast to these results, other stud-
ies [117,118], suggested that MVD (vessels marked by
CD31) is not a useful prognostic indicator for men with
clinically localized prostate cancer. Gettman et al [119]
concluded that MVD assessed by both OMVD (optimized
microvessel density) and AWMVD (area-weighted micro-
vessel density) did not predict recurrence of pathologic
stage T3 adenocarcinoma of prostate. Microvessel density
does not seem to be a prognosticator of disease-specific
survival as compared to conventional pathology com-
bined with p53 and retinoblastoma assessment [120].
p53
Mutations of the p53 tumour suppressor gene can result
in uninhibited cellular growth and have been implicated
in numerous malignancies [121]. In most human cancers,
increased immunohistochemical expression is associated
with point mutations in one allele of p53 gene and loss in
the other. Thomas et al [122] and Shurbaji et al [123] eval-
uated the immunohistochemical detection of p53 protein
in prostate cancer and its utility as a prognostic indicator.
They concluded that mutations of p53 gene, which have
long half-life, are involved in carcinogenesis of prostate
cancer, and that p53 reactivity marks an aggressive subset
of prostate cancer. To compare potential biologic markers
with laboratory, clinical and histopathologic parameters
and PSA level, tumour stage, tumour grade, and DNA con-
tent, Papadopoulos et al [103] characterized the prolifer-
ation marker Ki-S5, p53 expression, and ploidy status as
potential tumour biomarkers. High values of these mark-
ers in immunohistochemistry reflected poor prognosis.
Protein expression of p53, Ki-67, and bcl2 were evaluated
in archival paraffin-embedded radical prostatectomy
specimens from 162 patients of clinically localized cancer
by Moul et al [124] to determine the clinical use of p53,
Ki-67, and bcl2 immunohistochemical protein expression
in the primary tumour as combined predictors of disease
progression. The study concluded that p53, Ki-67, and
bcl2 have potential as biomarkers to predict recurrence in
patients with clinically localized prostate cancer after rad-
ical prostatectomy. All three markers were clearly corre-
lated with recurrence estimates at 6 years. The same
conclusion was obtained by Bauer et al [125].
Grignon et al [126] studied 471 patients to assess the
prognostic value of identifying abnormal p53 protein
expression in tumours of patients with locally advanced
prostate cancer who were treated with either external-
beam radiation therapy alone, or total androgen blockade
before and during the radiation therapy. Statistically sig-
nificant associations were found between the presence of
abnormal p53 protein expression and increased incidence
of distant metastases, decreased progression-free survival,
and decreased overall survival. Among patients receiving
both radiation therapy and hormone therapy, those with
tumours exhibiting abnormal p53 protein expression
experienced a reduced time to the development of distant
metastases.
Seventy-one patients with clinically localized prostate
cancer treated with radical prostatectomy were assessed by
Theodorescu et al [127] to investigate whether the levels
of immunoreactivity for p53, Rb, and bcl2 are better pre-
dictors of disease specific survival than conventional path-
ological parameters of the primary tumour, such as
Gleason's score, capsular penetration, seminal vesicleDiagnostic Pathology 2006, 1:4 http://www.diagnosticpathology.org/content/1/1/4
Page 9 of 15
(page number not for citation purposes)
invasion and percent of tumour in the specimen. They
found that high level staining of p53 and Rb are inde-
pendent factors predicting disease specific survival better
than low level staining. They concluded that p53 and Rb
immunohistochemical staining scores were superior to
conventional pathological prognostic factors of the pri-
mary tumour as predictors of disease specific survival. In
multivariate analysis, p53 overexpression was identified
as the only prognostic parameter for recurrence-free sur-
vival (P = 0.005) [128]. Further prospective studies are rec-
ommended to confirm the independent prognostic
potential of p53 overexpression in patients with localised
prostate cancer, but it seems that p53 expression has the
potential to become a dominant prognosticator in clinical
practice.
Scherr et al [129] evaluated the expression of two key reg-
ulators of apoptosis, bcl2 and p53, by immunohisto-
chemical staining on pre-treatment needle biopsies from
54 patients who were later treated with radiotherapy for
localized prostate cancer. They found that biopsies with
positive bcl2 and p53 expression were associated with
treatment failure after external beam radiation therapy.
These finding suggested that determination of bcl2 and
p53 expression in pre-treatment stage may be helpful for
predicting response to definitive radiotherapy.
p27
p27 is an inhibitor of the cell cycle with potential tumour
suppressor function; it belongs to the Cip/Kip family of
cyclin-dependent kinase inhibitory proteins which down
regulate cell proliferation. Decreased levels of p27 protein
expression have been correlated with poor prognosis in
patients with breast [130,131], lung [132], and ovarian
cancers [133].
To evaluate the prognostic value of p27 protein levels in
patients with localized prostate cancer, Yang et al [134]
examined 86 patients with clinical stage T1-2 prostate can-
cer who were treated with radical prostatectomy. The
archival paraffin embedded specimens were sectioned
and immunostained with p27 antibody, and scored by
two independent observers in a blind fashion. They found
that absent or low levels of p27 protein expression were
an adverse prognostic factor in patients with clinically
organ confined disease. This marker appears to be espe-
cially useful in patients with pathological stage T2-T3b
disease.
p21
p21/WAF1 protein is a cyclin-dependent kinase inhibitor
able to arrest the cell cycle at the G1 phase by inhibiting
DNA replication. To understand the molecular mecha-
nism leading to androgen-independent growth in prostate
cancer, Baretton et al [135] demonstrated that p21/WAF1
overexpression before and after androgen deprivation
therapy (ADT) characterized a subgroup of advanced
prostate cancer with paradoxically high proliferation rate.
Overexpressing cancers had significantly worse clinical
outcome than cancers with low expression level.
Another type of p21 (ras p21) was studied by Agnantis et
al [136]. They showed that ras p21 is detected in benign
and cancerous lesions of the prostate gland. The expres-
sion tends to be weak in adenomatous hyperplasia and
more intense in cancer. They found an inverse relation
between ras p21 positivity and the degree of differentia-
tion. The follow up of this study revealed a statistically sig-
nificant correlation between 5-year survival and p21
expression, more intense staining reflecting poor survival.
DNA ploidy
DNA content
The first report on the relationship of DNA ploidy of pros-
tate carcinoma with prognosis appeared in 1966 [137]. It
has been suggested that cytological smear preparations are
more suitable than tissue sections for determination of
DNA content and morphometric parameters such as
nuclear shape, size, and texture due to less overlap
between cells and between cell nuclei [138].
DNA studies have shown that patients with diploid can-
cers have longer disease-free interval and survival times
than those with non-diploid tumours [139]. However,
they may not be so helpful in predicting stage for an indi-
vidual patient. In a multivariate analysis Forsslund et al
[140] showed that DNA ploidy was a better predictor of
survival than histological grade and tumour stage. Frank-
furt and his colleagues [141] examined 45 patients with
prostate cancer and noted that all 11 patients with organ
confined cancer had diploid tumours. None of the aneu-
ploid tumours were organ confined. Blute et al [142]
selected two equal groups of age-matched patients for
study. The patients were followed for 5–21 years with a
median follow-up of 8 years. Both groups initially had
clinical and pathologic stage B disease and were treated
uniformly by radical surgery without adjuvant therapy.
Members of one group had disease progression, whereas
members of the other group did not. Although tumour
grade, capsular involvement, the number of tumour foci,
and tumour volume were evaluated in addition to DNA
ploidy, disease progression showed a significant relation-
ship with ploidy only. In the group with disease progres-
sion, 37% had diploid tumours, and 63% had non-
diploid tumours (of which 34% tetraploid and 29% ane-
uploid). In contrast, the group without progression had
92% diploid tumours, and 8% non-diploid tumours (all
tetraploid).Diagnostic Pathology 2006, 1:4 http://www.diagnosticpathology.org/content/1/1/4
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The most convincing evidence of the prognostic role of
DNA content comes from a study by Forsslund and Zetter-
berg [143] where DNA was measured in a series of
patients with a long-term follow-up. Patients who died
within 3 years of diagnosis consistently had DNA stem-
lines at 3c and 6c, whereas long-term survivors (> 15
years) had stemlines at 2c and 4c. Stephenson et al [144]
examined the ploidy value of cancer found in pelvic
lymph node metastases and observed a strong correlation
between mean survival time and ploidy status. In the
Mayo Clinic prostatectomy series, ploidy was one of the
significant predictive factors found in multivariate analy-
sis of tumour characteristics [145].
The long-term outcome of 790 patients with adenocarci-
noma of prostate treated with radical prostatectomy and
early androgen ablation was assessed retrospectively by
Seay and co-workers [146]. They found that diploid
tumours were less likely to have biochemical (PSA test),
local or systemic progression than non-diploid tumours.
They concluded that patients with diploid tumours had a
more favourable outcome than those with non-diploid
tumours when treated with androgen ablation therapy.
Ross et al [147] used needle biopsies for prediction of
pathological stage and disease recurrence after prostatec-
tomy by DNA ploidy analysis. The study showed a ten-
fold increase in risk for metastasis and three-fold risk for
extra-capsular spread if the initial needle biopsy demon-
strated non-diploidy. The authors concluded that ploidy
analysis was more important than grade in prediction of
outcome.
In a study of stage C prostate cancer, Lee S et al [148]
found that there was a greater likelihood for recurrent dis-
ease after surgery if tumours were non-diploid. The prob-
ability of a disease-free interval of 60 months was 85% for
those with diploid tumours as compared with only 9% for
those with non-diploid tumours. This advantage held
even in the presence of seminal vesicle involvement: 73%
of patients with diploid tumours and seminal vesicle
involvement remained free of disease during follow-up, as
compared with only 8% of those who had non-diploid
cancer and seminal vesicle involvement.
Buhmeida et al [149] studied the influences of sampling
rules on the appearance of histograms in fine needle aspi-
ration biopsies of prostate. He found that diploid or
peridiploid patterns were commonly found in cell groups
while tetraploid, peritetraploid, or aneuploid patterns
were clearly more common among free cells. The results
strongly suggested that measurements on cell groups were
less efficient in detecting abnormality than the measure-
ments done on free cells. The clinical relevance of the his-
togram patterns were also examined [150] with respect to
their significance in differentiating between benign and
malignant cells and also in estimating the stable or pro-
gressive character of prostate cancer. The aneuploidy pat-
terns and DNA histogram characteristics defined by the
presence of cells above cut-off points of > 5c, > 6c, > 7c
and > 8c seem to be useful in differentiation between the
stable and progressive characteristics of cancer, i.e.
between the more aggressive types of cancer and cancers
with slower progressive activity.
Cell proliferation
Ki-67
Ki-67 is one of several cell-cycle-regulating proteins,
which can be demonstrated by immunohistochemistry
[151,152]. It is a DNA-binding protein, which is expressed
in all phases of cell cycle but undetectable in resting cells
[153,154]. Ki-67 index (fraction of Ki-67 positive nuclei
in immunohistochemistry) was higher for carcinomas
than for hyperplastic glands. Within the group of carcino-
mas, Ki-67 indices in patients with metastatic disease were
significantly higher than in those without metastasis.
However, the results suggested that high Ki-67 index
could define a group of patients with poor prognosis
[155].
To identify associations between proliferative indexes
(including Ki-67 index) and disease progression follow-
ing radical prostatectomy, paraffin embedded specimens
from 180 patients were immunohistochemically stained
for Ki-67 antigen by Bettencourt and his colleagues [156].
They found that patients with a high Ki-67 antigen score
had earlier progression and a lower 5-year recurrence-free
survival rate than those with low or negative Ki-67 antigen
score (p < 0.001). The same was concluded by Bubendorf
et al [157]. The results of a study by Aaltomaa et al [158]
showed that Ki-67 expression is a potentially useful pre-
dictor of survival (p = 0.025) in prostatic adenocarci-
noma. In contrast to these studies, Ojea Calvo et al [159]
suggested that Ki-67 expression (3%) in preoperative
biopsies is less effective than classic factors such as PSA,
Gleason score, and pT classification in predicting prostate
cancer biochemical progression after radical prostatec-
tomy.
S-phase fraction
S-phase fraction (SPF) is the proportion of cells in the S
phase of the cell cycle. S-phase fraction can be estimated
from DNA flow cytometry (FC) histograms and also from
DNA static cytometry histograms [160]. The results based
on these two methods to evaluate proliferation parame-
ters generally give similar results [161,162]. Although that
some differences may exist. High SPF is associated with
shorter overall survival and shorter time to local progres-
sion and metastasis in clinically localized prostate cancer
[163]. Bratt et al [164] compared the prognostic signifi-
cance of S-phase fraction with chromosome aberrationsDiagnostic Pathology 2006, 1:4 http://www.diagnosticpathology.org/content/1/1/4
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and DNA ploidy in prostate adenocarcinoma. They found
that SPF as determined with FC was superior to karyotype
and ploidy in predicting poor survival in prostate cancer.
Gene expression profiling
DNA microarray technology is revolutionizing the way
fundamental biologic questions are addressed in the post-
genomic era. Microarrays allow a simultaneous gene
expression analysis of thousands of genes, providing an
expression profile of the specimen investigated. The idea
is to find gene expression profiles associated with good or
poor clinical outcome in terms of survival or in terms of
treatment response in prostate cancer [165,166]. The
progress in this field has been shown particularly in breast
cancer [167,168]. The use of a microarray based prognos-
tic tool in prostate cancer is under development. How-
ever, some studies have implemented high-density DNA
microarrays to analyze prostate cancer specimens [169-
171]. Gene expression profiles of invasive and organ-con-
fined prostate cancer have been established [172], as these
have been correlated with clinical behaviour [173].
Conclusion
The majority of prostate carcinomas never progress to
clinically significant disease. A minor fraction of the clin-
ical cases remains confined to the prostate for many years
and other carcinomas progress rapidly to a life threatening
disease. How to distinguish these three biologically differ-
ent types [174], is a question of great importance. Pathol-
ogists play an important role in preoperative diagnosis
and in the postoperative prognostic evaluation. Most
research results currently available were based on radical
prostatectomy specimens to find markers on the basis of
disease progression could be predicted. This means that
they need to be tested on biopsy material before the treat-
ment decision to be taken. But the multifocal and hetero-
geneous nature of prostate cancer makes it difficult to
obtain a representative biopsy sample. Improvements in
biopsy procedures will be mandatory in order to make
progress on this issue [175,176].
Histological grading is a very important factor for the
assessment of prognosis. Although the reproducibility is
not perfect, still the Gleason's grading system is the most
favoured prognostic factor, and highly significantly asso-
ciated with survival and/or progression. Additionally, the
volume of the tumour, vascular invasion, extension of the
tumour through the prostate capsule, and invasion to the
seminal vesicle might be valid prognostic factors for dis-
ease progression and survival. The value of different
biomarkers (p53, ki-67, androgen receptor mutations,
IGF, E-cadherin) remains to be applied in clinical practice
[171,177,178].
DNA ploidy is a good prognostic factor after prostatec-
tomy and can be used in planning therapy. Unfortunately
DNA ploidy measurements from biopsies are rare in clin-
ical practice, in spite of the extensive literature that sup-
ports their use [173]. Compound prognostic factors based
on the gene expression profiles (tested by DNA arrays) are
promising and will accelerate the discovery of new predic-
tive and prognostic molecules, but clinically relevant data
up to this moment are still lacking [179]. Multivariate
analyses of prognostic factors are enough, and multivari-
ate models for prediction of compound prognosticators
or predictors have not been well tested in clinical practice.
Approximately one third of clinically localized prostate
cancer treated by radical prostatectomy will recur within
10 years. To prevent recurrence, new adjuvant therapies
are in development for treating high-risk patients after
surgery [180-182]. To identify good candidates for these
treatments, there is still a need for new biomarkers that
potentially will improve the ability of evaluation of the
prognostic or predictive status of the patient [183].
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